Peripheral T Cell Lymphoma Clinical Trial
Official title:
Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma
Despite the use of monoclonal antibodies, checkpoint inhibitors, and bispecific T cell adapters (BiTE) Immunotherapies such as chimeric antigen receptor (CAR) T cells have completely changed the treatment methods of various cancers. However, only limited responses were observed in T cell diseases, In CD30 positive PTCL and CTCL patients. The use of BV in and pembroluzimab (Programmed cell death receptor 1) in the treatment of ENKTL. Although some promising results have been observed for (PD-1) inhibitors, these positive results are limited to specific subtypes of T cell diseases. CAR T Cell therapy in recurrent/refractory B-cell malignant tumors is very successful, the Food and Drug Administration (FDA) has approved two CAR T Cell therapy for the treatment of this type of disease. However, using this technology to treat T-cell malignancies has always been difficult, mainly due to the lack of tumor specific surface antigens in cancerous T cells. Therefore, our center plans to conduct a phase I clinical study of CAR-T to explore the possibility of bringing more treatment options and benefits to PTCL patients.
Patients with recurrent/refractory PTCL were included using a single arm, open label, and single center approach. Pre treatment plan: Cyclophosphamide (CTX): 500mg/m2 × 3 days Fludarabine: 30mg/m2 × 3 days Note: Researchers can adjust the pre-treatment plan appropriately based on the patient's condition, such as CTX 300mg × Wait for 3 days. CTX and Flu were infused on the 5th to 3rd day (D-5 to D-3) before administration. RD13-02 can only be injected after 48 hours of pre-treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04526834 -
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04390737 -
Evaluate the Safety and Clinical Activity of HH2853
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05559008 -
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06083701 -
Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT02856997 -
Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT04083495 -
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT04984837 -
Study of Lacutamab in Peripheral T-cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT06072131 -
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
|
Phase 3 | |
| Completed |
NCT01716806 -
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
|
Phase 2 | |
| Terminated |
NCT03947255 -
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT04028440 -
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
|
Early Phase 1 | |
| Not yet recruiting |
NCT05923502 -
(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
|
||
| Recruiting |
NCT05883449 -
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
|
Phase 2 | |
| Recruiting |
NCT05377827 -
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT03586999 -
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04489264 -
The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma
|
||
| Recruiting |
NCT06151106 -
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT02753543 -
Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma
|
Phase 2 | |
| Not yet recruiting |
NCT06089941 -
Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas
|
||
| Recruiting |
NCT06131801 -
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
|